Study of the change of dietary intake and contents after taking selective SGLT2 inhibitor, Ipragliflozi

Phase 4

Recruiting

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000015952
• Lead Sponsor: A society for the study of SGLT2 in Aomori-ken

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-12-15
• Study Completion: 2016-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with allergy for Ipragliflozin 2) Patients got severe ketosis, diabetic coma, and diabetic precoma during the past 6 months 3) Patients with severe infectious disease and injury, and in perioperative 4) Patients with renal dysfunction at a moderate level or high 5) Patients whose doctor judges to unfit for this study

Study & Design

• Study Type: Interventional,observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
We investigate HbA1c, GA, body weight, waist circumstance, body composition, and appearance of harmful phenomenon at initial and screening visits (3 month, 6 month, and 12 month after taking Ipragliflozin).

Secondary Outcome Measures

Name	Time	Method
We investigate the dietary intake and contents at initial and screening visits (3 month, 6 month, and 12 month after taking Ipragliflozin).